
Globus Medical (GMED) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
598.1M
Gross Profit
402.7M
67.33%
Operating Income
98.1M
16.39%
Net Income
75.5M
12.62%
EPS (Diluted)
$0.54
Balance Sheet Metrics
Total Assets
4.7B
Total Liabilities
623.1M
Shareholders Equity
4.1B
Debt to Equity
0.15
Cash Flow Metrics
Operating Cash Flow
193.8M
Free Cash Flow
136.2M
Revenue & Profitability Trend
Globus Medical Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 2.5B | 1.6B | 1.0B | 958.1M | 789.0M |
Cost of Goods Sold | 1.0B | 548.2M | 263.7M | 239.2M | 217.5M |
Gross Profit | 1.5B | 1.0B | 759.1M | 718.9M | 571.6M |
Gross Margin % | 58.9% | 65.1% | 74.2% | 75.0% | 72.4% |
Operating Expenses | |||||
Research & Development | 163.8M | 124.0M | 73.0M | 97.3M | 84.5M |
Selling, General & Administrative | 981.0M | 643.4M | 432.1M | 408.1M | 354.8M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 1.1B | 767.4M | 505.1M | 505.5M | 439.3M |
Operating Income | 219.7M | 201.8M | 236.3M | 194.9M | 115.5M |
Operating Margin % | 8.7% | 12.9% | 23.1% | 20.3% | 14.6% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | - | - | - | - | - |
Other Non-Operating Income | -94.8M | -56.6M | -7.5M | -23.7M | -3.5M |
Pre-tax Income | 120.7M | 165.4M | 243.0M | 180.4M | 125.9M |
Income Tax | 17.7M | 42.5M | 52.8M | 31.2M | 23.6M |
Effective Tax Rate % | 14.7% | 25.7% | 21.7% | 17.3% | 18.8% |
Net Income | 103.0M | 122.9M | 190.2M | 149.2M | 102.3M |
Net Margin % | 4.1% | 7.8% | 18.6% | 15.6% | 13.0% |
Key Metrics | |||||
EBITDA | 570.7M | 401.0M | 313.8M | 289.1M | 182.7M |
EPS (Basic) | $0.76 | $1.09 | $1.89 | $1.48 | $1.04 |
EPS (Diluted) | $0.75 | $1.07 | $1.85 | $1.44 | $1.01 |
Basic Shares Outstanding | 135726000 | 113087000 | 100469000 | 100734000 | 98580000 |
Diluted Shares Outstanding | 135726000 | 113087000 | 100469000 | 100734000 | 98580000 |
Income Statement Trend
Globus Medical Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 784.4M | 467.3M | 150.5M | 193.1M | 239.4M |
Short-term Investments | 105.6M | 50.5M | 295.6M | 250.4M | 187.3M |
Accounts Receivable | 557.7M | 503.2M | 213.2M | 164.4M | 141.7M |
Inventory | 659.2M | 848.1M | 299.0M | 237.0M | 229.2M |
Other Current Assets | 49.6M | 44.6M | 21.0M | 18.4M | 17.8M |
Total Current Assets | 2.2B | 1.9B | 983.3M | 864.5M | 821.8M |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.0B | 960.4M | 533.0M | 473.7M | 451.2M |
Goodwill | 3.7B | 3.8B | 458.5M | 428.1M | 400.4M |
Intangible Assets | 795.1M | 924.6M | 63.6M | 68.7M | 86.9M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 169.3M | 89.3M | 86.2M | 60.8M | 38.7M |
Total Non-Current Assets | 3.1B | 3.2B | 1.1B | 1.1B | 857.7M |
Total Assets | 5.3B | 5.1B | 2.1B | 2.0B | 1.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 75.1M | 56.7M | 36.1M | 22.0M | 18.2M |
Short-term Debt | 453.6M | 12.0M | 2.5M | - | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 33.7M | 61.0M | 13.3M | 11.8M | 5.8M |
Total Current Liabilities | 855.9M | 392.3M | 159.2M | 140.2M | 120.8M |
Non-Current Liabilities | |||||
Long-term Debt | 83.6M | 508.4M | 3.5M | - | - |
Deferred Tax Liabilities | 23.9M | 84.4M | 1.8M | 4.3M | 6.2M |
Other Non-Current Liabilities | 111.0M | 102.9M | 65.3M | 71.4M | 46.2M |
Total Non-Current Liabilities | 218.5M | 695.8M | 70.5M | 75.7M | 52.4M |
Total Liabilities | 1.1B | 1.1B | 229.8M | 215.9M | 173.2M |
Equity | |||||
Common Stock | 137.0K | 136.0K | 100.0K | 101.0K | 99.0K |
Retained Earnings | 1.2B | 1.1B | 1.2B | 1.2B | 1.0B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 4.2B | 4.0B | 1.8B | 1.7B | 1.5B |
Key Metrics | |||||
Total Debt | 537.2M | 520.4M | 6.0M | 0 | 0 |
Working Capital | 1.3B | 1.5B | 824.1M | 724.4M | 701.0M |
Balance Sheet Composition
Globus Medical Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 103.0M | 122.9M | 190.2M | 149.2M | 102.3M |
Depreciation & Amortization | 254.0M | 144.7M | 68.3M | 69.9M | 62.9M |
Stock-Based Compensation | 54.2M | 52.7M | 32.8M | 30.6M | 27.1M |
Working Capital Changes | -103.6M | -134.9M | -101.1M | -29.0M | -44.1M |
Operating Cash Flow | 444.1M | 221.9M | 170.6M | 254.0M | 170.2M |
Investing Activities | |||||
Capital Expenditures | -115.4M | -78.3M | -74.0M | -56.9M | -63.7M |
Acquisitions | -17.6M | -296.0M | -31.4M | -34.5M | -33.5M |
Investment Purchases | -113.5M | -100.6M | -419.5M | -622.4M | -223.5M |
Investment Sales | 70.5M | 777.9M | 414.7M | 337.8M | 203.4M |
Investing Cash Flow | -176.1M | 303.0M | -110.4M | -375.9M | -117.3M |
Financing Activities | |||||
Share Repurchases | -85.8M | -225.6M | -144.5M | 0 | -104.7M |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | -138.1M | -244.2M | -151.7M | 54.1M | -38.7M |
Free Cash Flow | 405.2M | 165.2M | 104.4M | 219.4M | 135.1M |
Net Change in Cash | 129.9M | 280.7M | -91.5M | -67.8M | 14.2M |
Cash Flow Trend
Globus Medical Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
23.98
Forward P/E
18.09
Price to Book
1.95
Price to Sales
3.18
PEG Ratio
18.09
Profitability Ratios
Profit Margin
13.58%
Operating Margin
17.33%
Return on Equity
8.62%
Return on Assets
5.82%
Financial Health
Current Ratio
4.07
Debt to Equity
2.83
Beta
1.20
Per Share Data
EPS (TTM)
$2.58
Book Value per Share
$31.81
Revenue per Share
$19.30
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
gmed | 8.4B | 23.98 | 1.95 | 8.62% | 13.58% | 2.83 |
Abbott Laboratories | 228.0B | 16.44 | 4.51 | 30.93% | 32.43% | 26.50 |
Boston Scientific | 152.2B | 60.80 | 6.78 | 11.55% | 13.55% | 53.09 |
Penumbra | 9.7B | 65.75 | 7.46 | 12.03% | 11.54% | 17.04 |
Masimo | 8.2B | 129.16 | 7.82 | -22.37% | -21.32% | 61.58 |
Bio-Rad Laboratories | 7.4B | 24.80 | 1.04 | 4.59% | 12.50% | 19.73 |
Financial data is updated regularly. All figures are in the company's reporting currency.